Anthera Pharmaceuticals

Anthera Pharmaceuticals is a technology company.

Active

Updated: Mar 21, 2026 ·

About

Anthera Pharmaceuticals developed biopharmaceutical treatments targeting serious inflammatory, autoimmune conditions, and cystic fibrosis. The company's pipeline focused on innovative therapies, including Blisibimod, an antagonist of B-cell activating factor intended for autoimmune disorders, and Sollpura, a therapeutic candidate designed to address exocrine pancreatic insufficiency. Its technical approach involved advancing drug candidates through clinical trials to commercialization for conditions with significant unmet medical needs.

The company was founded in 2004 by Paul F. Truex, an experienced pharmaceutical industry executive. Anthera Pharmaceuticals originated from the insight that novel drug discovery and development could effectively address critical therapeutic gaps in complex diseases. Truex leveraged his background to establish the company's research and development focus, building its pipeline of specialized drug candidates.

Anthera Pharmaceuticals aimed to serve patient populations suffering from chronic debilitating diseases such as IgA nephropathy and cystic fibrosis-related exocrine pancreatic insufficiency. The company's vision centered on successfully bringing these innovative, commercial-stage medicines to market. By doing so, Anthera sought to substantially improve the quality of life for these underserved patient populations through targeted pharmacological interventions.

Recent News & Mentions

Aug 1, 2008FundingAnthera Pharmaceuticals - Venture Round Sep 1, 2006FundingAnthera Pharmaceuticals - Venture Round

Financial History

Anthera Pharmaceuticals has raised $55.0M across 2 funding rounds. Most recently, it raised $19.0M Venture Round in August 2008.

Total Raised

$55.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Aug 1, 2008	$19.0M Venture Round		Sofinnova Investments, VantagePoint Capital Partners
Sep 1, 2006	$36.0M Venture Round		Sofinnova Investments, VantagePoint Capital Partners

Financial History

Anthera Pharmaceuticals has raised $55.0M across 2 funding rounds.

Total Raised

$55.0M

Valuation

N/A

Deep Dive

High-Level Overview

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with unmet medical needs, particularly in rare and serious diseases. Its key products under development include Sollpura, a non-porcine pancreatic enzyme replacement therapy targeting exocrine pancreatic insufficiency, currently in Phase III clinical trials, and Blisibimod, a treatment for B-cell mediated autoimmune diseases such as IgA nephropathy, in Phase II trials. The company primarily serves patients with these conditions and aims to address significant therapeutic gaps in these areas[1].

Origin Story

Founded in 2004 and based in Houston, Texas, Anthera Pharmaceuticals was established to advance novel therapies for difficult-to-treat diseases. The company has evolved its focus around developing proprietary drug candidates with strong clinical potential, leveraging partnerships with major pharmaceutical companies like Amgen and Eli Lilly to support its development efforts. Early milestones include progressing its lead candidates through clinical trials, which have been pivotal in validating its approach and attracting licensing collaborations[1].

Core Differentiators

Product Differentiators: Anthera’s lead product, Sollpura, is distinguished by being a non-porcine pancreatic enzyme replacement, which may offer advantages in safety or tolerability compared to existing porcine-derived therapies.
Clinical Pipeline: The company maintains a focused pipeline with candidates addressing rare and autoimmune diseases, areas with high unmet medical needs.
Strategic Partnerships: License agreements with established pharmaceutical companies enhance its development capabilities and commercial potential.
Small, Specialized Team: With a lean workforce, Anthera emphasizes efficient clinical development and regulatory expertise to advance its programs[1].

Role in the Broader Tech Landscape

Anthera operates within the biotechnology sector, riding the broader trend of precision medicine and targeted therapies for rare diseases and autoimmune conditions. The timing is favorable due to increasing regulatory support for orphan drugs and growing patient demand for novel treatments where few options exist. By focusing on niche indications with significant unmet needs, Anthera contributes to expanding therapeutic options and potentially improving patient outcomes in specialized markets. Its collaborations with larger pharma players also integrate it into the wider pharmaceutical innovation ecosystem[1].

Quick Take & Future Outlook

Looking ahead, Anthera Pharmaceuticals’ success will hinge on the clinical and regulatory progress of its lead candidates, particularly Sollpura’s Phase III trial outcomes. Positive results could pave the way for commercialization and broader market impact. Trends such as personalized medicine, regulatory incentives for rare disease drugs, and increasing autoimmune disease prevalence will shape its trajectory. As it advances, Anthera may expand its influence by delivering differentiated therapies that address critical gaps in treatment, potentially attracting further partnerships or acquisition interest.

In summary, Anthera Pharmaceuticals is a focused biotech company developing innovative therapies for underserved patient populations, positioned to leverage clinical progress and market trends to enhance its role in the healthcare landscape[1].

Sources

Frequently Asked Questions

How much funding has Anthera Pharmaceuticals raised?

Anthera Pharmaceuticals has raised $55.0M in total across 2 funding rounds.

Who are Anthera Pharmaceuticals's investors?

Anthera Pharmaceuticals's investors include Sofinnova Investments, VantagePoint Capital Partners.